September 26, 2024 09:00 PM EDT
R&D
Special

End­points 11 win­ner Xaira Ther­a­peu­tics: Biotech’s largest AI bet with A-list back­ers

Andrew Dunn

Senior Biopharma Correspondent

↑
  • CEO Marc Tessier-Lav­i­gne
  • To­tal raised More than $1 bil­lion in com­mit­ted cap­i­tal
  • Head­quar­ters South San Fran­cis­co, CA

David Bak­er’s Seat­tle …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times